Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma.
Ya-Hsuan ChangChih-Hsiang YuMeng-Yao LuShiann-Tarng JouChien-Yu LinKai-Hsin LinHsiu-Hao ChangYu-Ling NiShu-Wei ChouKuan-Yin KoDong-Tsamn LinWen-Ming HsuHsuan-Yu ChenYung-Li YangPublished in: Pediatric blood & cancer (2024)
Genome sequencing to determine the tumor mutational burden and ALK variations can improve the risk classification of neuroblastoma and inform treatment.